**Appendix Table E117. Results from studies assessing the ability of miscellaneous platelet function tests to predict platelet reactivity during followup (discrete outcome) in patients with ischemic heart disease**

| **Author, year**  **UID**  **Country**  **Study name** | **Treatment** | **Phenotypic Test Used [index test]** | **Reactivity Outcome** | **Outcome Definition** | **Timing of measurement** | **Index test result: category (e.g., HPR+) – ONE ROW PER PHENOTYPE GROUP** | **Outcome status (e.g., HPR+ or HPR−)** | **No. with outcome status within phenotype group** | **Cut-off** | **Comparative metric (OR, RR, HR)** | **95% CI** | **P (between which groups?)**  **[statistical test]** | **Adjusted?**  **[YES/NO/NR]**  **If YES, for what factors?** | **Procedures for multiple comparisons [YES, NO, NR]** | **Comments (e.g., additional data in figures)** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Dziewierz,  2005  15815794  Poland  NR | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation | DPAI | The degree of platelet aggregation | 3h | Non-responder | Non-responder | 15/31 (48.4) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder | responder | 16/31 (51.6) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation | DPAI | The degree of platelet aggregation | 6h | Non-responder | Non-responder | 8/31 (25.8) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder | responder | 23/31 (74.2) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation | DPAI | The degree of platelet aggregation | 12h | Non-responder | Non-responder | 8/31 (25.8) | 10% | NR | NR | NR | NR | NR |  |
|  |  |  |  |  |  | responder | responder | 23/31 (74.2) |  |  |  |  |  |  |  |
|  | Clopidogrel LD 300 mg, 75mg maintain dose | Platelet aggregation | DPAI | The degree of platelet aggregation | 24h | Non-responder | Non-responder | 7/31 (22.6) | 10% | NR | NR | 1.0 (fishers exact between categories) | NR | NR |  |
|  |  |  |  |  |  | responder | responder | 24/31 (77.4) |  |  |  |  |  |  |  |
| Lindvall,  2009  19477870  Sweden  None | 300-600mg LD Clopidogrel and MD 75 mg/day+75mg daily aspirin | ADP-induced aggregation | Clopidogrel response vs nonresponse | Response defined as >90% aggregation | Repeat measurement immediately after aprotinin | Baseline HPR+  N = 4 | HPR- | 1 | >90% | NR | NR | 0.07(fishers exact between categories) | NR | NR |  |
|  |  |  |  |  |  | Baseline HPR-  N = 11 | HPR+ | 2 |  |  |  |  |  |  |  |
| Gurbel ,  2003  12714161  USA  No | 300mg LD clopidogrel and 75mg daily MD with 325 mg/day aspirin | Flow cytometry for P-selectin expression | Continued nonresponse since baseline | NR | 5 days | Nonresponders at baseline (n=9) | Nonresponders at 5 days | 5/9 (56%) | <10% change from baseline | NR | NR | 0.144 (fishers exact between categories) | NR | NR | NONE |
|  |  |  |  |  | 5 days | Responders at baseline (n=29) | Responders at 5 days | 29/29 (100%) |  |  |  |  |  |  |  |
|  |  |  |  |  | 30 days | Nonresponders at baseline (n=9) | Nonresponders at 30 days | 3/6 (50%) with data (3 were not measured at 30 days) |  |  |  |  |  |  |  |
|  |  |  |  |  | 30 days | Responders at baseline (n=29) | Responders at 30 days | 14/18 (78%) with data (11 were not measured at 30 days) |  |  |  |  |  |  |  |
| Kalantzi, 2012  21806493  Greece | LD 600mg clopidogrel+MD 75 mg/day | CD40L, PMP,  FACS  Calibur flow cytometer | CD40L, PMP,  FACS  Calibur flow cytometer | CD40L, PMP,  FACS  Calibur flow cytometer | 30 days | responder | responder by PRI >50% | 12 | NR | NR | NR | NR | NR | NR | figure 1, 2 |
|  |  |  |  |  | 30 days | non-responder |  | 28 |  |  |  |  |  |  |  |